Waldencast plc Warrant (WALDW) last traded on October 2, 2026. A Form 15-12G filed on October 15, 2026 ends the SEC registration of its shares.
What Changed
Price Move History
- Daily moves over 5%
- 104 195 sessions, October 1, 2025 to October 2, 2026
- Largest daily move
- +102.9% close of September 18, 2026
- 1-year change
- -82.7% closing prices, October 1, 2025 to October 2, 2026
- 1-month change
- -76% closing prices, September 2, 2026 to October 2, 2026
Company Description
Written before these shares stopped trading.
Waldencast plc (WALDW) is described as a beauty and wellness operating platform within the manufacturing sector, classified under all other miscellaneous chemical product and preparation manufacturing. According to available information, the company focuses on brands and products in the broader beauty and skin health space, with activities that include developing, marketing, and selling beauty-related formulations.
The company is organized into two reportable segments: Obagi Medical and Milk Makeup. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products under the Obagi Medical brand. The Milk Makeup segment involves developing, marketing, and selling cosmetics, skincare, and other beauty products. Based on disclosed segment information, Waldencast plc indicates that a significant portion of its revenue is associated with the Obagi Medical segment, underscoring the importance of skin health products within its overall business.
Waldencast plc is a foreign private issuer that reports to the U.S. Securities and Exchange Commission on Form 20-F and Form 6-K. The company has identified its principal executive office in London, United Kingdom. As a filer under the Securities Exchange Act of 1934, it periodically furnishes current reports on Form 6-K to provide updates on business developments and regulatory or commercial milestones.
Business segments and brand focus
The Obagi Medical segment centers on skin health products. In a Form 6-K current report, Waldencast plc announced that it had issued an announcement titled “Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand.” This highlights that the Obagi Medical segment includes products that may be subject to regulatory review and approval, such as injectable hyaluronic acid gel formulations under the Obagi brand.
The Milk Makeup segment includes cosmetics, skincare, and other beauty products. While detailed product lists are not provided in the available materials, the description of this segment emphasizes that it is focused on beauty and skincare offerings marketed under the Milk Makeup name.
Geographic and industry context
According to prior descriptive information, Waldencast plc generates a majority of its revenue from the North America region. Within the manufacturing sector, and specifically within all other miscellaneous chemical product and preparation manufacturing, its activities relate to the formulation and commercialization of beauty and skin health products, including those that may fall within regulated categories.
Regulatory and reporting profile
As indicated in its Form 6-K filings, Waldencast plc files under Form 20-F and uses Form 6-K to furnish press releases and business updates. One Form 6-K notes that the company provided business and financial updates and described progress on business priorities and initiatives to drive transformation, with a related press release attached as an exhibit. Another Form 6-K references the FDA approval of an Obagi-branded injectable hyaluronic acid gel product, also communicated via an attached company announcement.
These filings show that investors and observers can expect Waldencast plc to use SEC current reports to communicate material developments related to its brands, regulatory milestones, and broader business priorities.
Warrants and WALDW symbol
The symbol WALDW refers to warrants associated with Waldencast plc. The Form 6-K filings provided are identified as “Waldencast plc Warrant Current Report (Foreign Issuer),” indicating that these reports relate to the issuer whose warrants trade under WALDW. The filings themselves focus on company-level developments, and the warrant symbol provides a way for market participants to access exposure linked to Waldencast plc through derivative securities.
Evergreen considerations for investors and observers
From the available information, several structural aspects of Waldencast plc appear central and relatively stable over time:
- It operates as a beauty and wellness platform within the manufacturing sector.
- It reports two main segments: Obagi Medical and Milk Makeup.
- The Obagi Medical segment is associated with skin health products and, in at least one case, an FDA-approved injectable hyaluronic acid gel under the Obagi Medical brand.
- It is a foreign private issuer that uses Form 20-F and Form 6-K for SEC reporting.
- Its principal executive office is located in London, United Kingdom.
These elements provide a structural overview of how Waldencast plc presents its business and regulatory profile, without relying on time-sensitive performance metrics.
Stock Performance
Waldencast plc Warrant (WALDW) closed at $0.0067 on October 2, 2026. In the 12 months to October 2, 2026, the price lost 82.7%.
WALDW Metrics & Rankings
Price returns through October 2, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
Waldencast plc Warrant has 1 recent news article. Key topics include acquisition. View all WALDW news →
SEC Filings
Waldencast plc Warrant has filed 10 recent SEC filings, including 4 Form 4, 4 Form 6-K, 1 Form 25, 1 Form 15-12G. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all WALDW SEC filings →
Financial Highlights
Waldencast plc Warrant generated $272.1M in revenue in FY2025, retaining a 67.3% gross margin, operating income reached -$217.5M (-80.0% operating margin), and net income was -$229.7M, reflecting a -84.4% net profit margin. Diluted earnings per share stood at -$2.01. The company generated -$12.8M in operating cash flow. The current ratio was 1.70, measuring current assets divided by current liabilities.
Upcoming Events
Short Interest History
Short interest in Waldencast plc Warrant (WALDW) currently stands at 8.9 thousand shares, down 86.8% from the previous reporting period. Since November 2025, short interest has decreased by 54.1%.
Days to Cover History
Days to cover for Waldencast plc Warrant (WALDW) currently stands at 1.0 days. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has decreased by 93%. Across the settlements charted above, it has ranged from 1.0 to 36.1 days.
WALDW Company Profile & Sector Positioning
Waldencast plc Warrant (WALDW) .
Investors comparing WALDW often look at related companies in the same sector, including Grupo Financiero Galicia SA (GGAL), Himalaya Shipping Ltd. (HSHP), Southern Copper Corporation (SCCO), HDFC Bank Limited (HDB), and Ares Management Corporation (ARES). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate WALDW's relative position within its industry.